Krystal Biotech, Inc. Revenue 2016–2025
Krystal Biotech, Inc. reported $389.13M of revenue for fiscal 2025. That was 33.9% higher than fiscal 2024.
| Fiscal year | Revenue | Change (YoY) |
|---|---|---|
| FY 2025 | $389.13M | +33.9% |
| FY 2024 | $290.51M | +473.0% |
| FY 2023 | $50.70M | — |
| FY 2022 | $0 | — |
| FY 2021 | $0 | — |
| FY 2020 | $0 | — |
| FY 2019 | $0 | — |
| FY 2018 | $0 | — |
| FY 2017 | $0 | — |
| FY 2016 | $0 | — |
Source: Krystal Biotech, Inc. SEC filings — income statement (10-K). Computed deterministically; refreshed nightly (last updated August 2, 2026). Open KRYS 10-K filings at SEC EDGAR · Methodology · Download CSV.
How to read this history
Krystal Biotech, Inc. reported $389.13M of revenue for fiscal 2025. That was 33.9% higher than fiscal 2024. Values remain missing when the cached filing does not disclose a comparable line item; they are never estimated. Stock splits, reorganizations and fiscal-calendar changes can reduce comparability.
Prepared and reviewed by the stockportfolio.pro research desk. Corrections: support@stockportfolio.pro.
See the full picture for Krystal Biotech, Inc.
Complete income statement, balance sheet and cash flow with trend on every row, 48 quarters, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open the interactive view — freeKrystal Biotech, Inc. — frequently asked questions
What is Krystal Biotech, Inc.'s revenue?
Krystal Biotech, Inc. (KRYS) reported revenue of $389.13M for fiscal year 2025, per its SEC filings.
Where does this data come from?
Figures are computed from Krystal Biotech, Inc.'s official SEC filings (income statement (10-K)), refreshed nightly. Not investment advice.